OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Cambridge, Mass. - An experimental therapy that makes use of fibroblast growth factor type 1 (FGF-1) encoded in naked plasmid DNA (NV1FGF) could save the limbs of patients afflicted with chronic wounds due to critical leg ischemia associated with peripheral arterial disease (PAD), according to Vincent Li, M.D., M.B.A.
Related Content:
News